BioAtla IPO Presentation Deck

AXL Targeting: Opportunity to Fill Treatment Void in Sarcomas bicatla Unmet need drives lower regulatory hurdles and higher market demand, representing opportunity -57% of our Sarcoma patients are AXL positive (TmPS ≥ 70)¹, supporting AXL opportunity BA3011 (AXL-ADC) has high potential to treat sarcoma successfully and fulfill opportunity Unmet Need for Sarcomas • Bone sarcomas have no approved therapies after failure of frontline regimens • No targeted therapies available for most soft tissue sarcoma • Low 5-year survival rates (-16.4% for late-stage metastatic soft tissue sarcoma) Lower Regulatory Hurdles for Sarcoma Treatments • Approved therapies generally show improved ORRS² of less than 15% 100% 75% 50%- 25% Pembrolizumab Nivolumab Eribulin Pazopanib Dacarbazine Figitumumab Aldoxorubican Yondelis Pembrolizumab //// Doxorubicin Apatinib Tazemeostat * Approved Gemacitabine *Docetaxel Cabozantinib 15% ORR Large and Under-Appreciated Commercial Opportunity • Lilly's olaratumab given accelerated approval for combination treatment for sarcoma in 2016 • Before withdrawal from market for failing Phase 3, olaratumab had sales of $562 million with a 50% CAGR, in less than 2 years Note: TmPS-Tumor membrane Percent Score- Scores range from 0 to 100, "Objective response rates (ORR) is defined as the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period and is comprised of complete responses and partial responses; Pembrolizumab ORR data from 2015-2016 Pembrolizumab ORR data from 2017 SORR for Gemcitabine treatment in combination with Docetaxel 11

View entire presentation